Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | Beyond the scientific challenges of paediatric cancer, economic barriers are a key reason why fewer cancer therapies reach children and young people.
Sam Daems is a Portfolio Director at Waterland Private Equity and a patient advocate with the PROTECT Cancer Grand Challenges team. Writing for Cancer News for Researchers, Sam explores why traditional drug discovery models so far have failed.
Sam discusses how small patient populations, which make clinical trial recruitment harder and delays the time to market for new treatments, as well as the unfavourable risk-return balance, all contribute towards discouraging pharmaceutical companies from investing in paediatric oncology.
To address these challenges, the newly launched international consortium C-Further is taking a fresh approach, providing resourcing and funding to deliver new therapeutics for children’s and young people’s cancer.
|
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
#CRUK-Funded: UK’s first vaccine to prevent cancer in people with Lynch syndrome |
| David Church, Simon Leedham and colleagues at the University of Oxford are developing ‘LynchVax’, the UK’s first vaccine to prevent cancer in people with Lynch syndrome, a heritable genetic condition that increases the risk of bowel and other cancers.
The team has been awarded up to £550,000 by us to carry out the initial underpinning work to test the vaccine’s potential. They will define resulting frameshift peptides in Lynch syndrome associated pre-cancers and determine the mechanisms of immune escape. If successful, the vaccine in development will teach the immune system to identify pre-cancer cells and destroy them before they become cancer.
Meanwhile, the team will also consult the wider Lynch syndrome community to gather their views on a vaccine approach to prevent cancer.
LynchVax is one of several projects funded under our prevention research strategy, which aims to find more precise ways to prevent cancer.
|
| | |
|
|
|
| | | | | We’ve invested £84m into basic research, £93m into research relevant to all types of cancer and £164m into specific cancer types. We’re on track to spend £1.5bn on research over a five-year period – in line with our research strategy.
Some milestones from the last year include our innovation engine, Cancer Research Horizons, progressing five research projects into clinical trials, and creating five new spin-out companies that will accelerate the development of new cancer medicines. Over the last year, two new drugs we helped to develop, Akeega™ and Truqap™, have been released for use.
To hear more about our impact and dive deeper into our research spend this year take a look at our 23/24 annual report. | | |
| | | | | | | Do you work in paediatric oncology? Find out more about C-Further and what projects its looking for.
Join online on 18 September, from 4–5 PM (BST), to hear from Cancer Research Horizons and LifeArc about the new consortium’s drug discovery capabilities, what a well-validated target looks like, what the different drug discovery stages mean and how to apply for support to translate your discoveries. | | |
|
|---|
|
|
|
|
| | The promise of proteomics for cancer prevention |
| | After winning the poster prize at our inaugural Cancer Prevention Research Conference in Boston, we caught up with Zhe Huang to talk about his work on investigating the proteomic profiles of prostate cancer, his trip to Boston and the story behind his early career.
Hear more from Zhe about how proteomic research is shaking up the prevention space, as well as advice for those who have newly stepped in the prevention field. |
| | |
|
|
|---|
|
|
|
|
|
First Cancer Grand Challenges spin-out launches |
| Data generated in the life sciences is increasing in size and becoming more and more complex and so improving data visualisation and analysis is more important than ever.
Using the unique medium of virtual reality, new start-up Suil Vision aims to develop a powerful data visualisation and analysis tool that is compatible with many data sources and accessible to researchers with limited programming skills. It will preserve the position, type, shape, and genetic data of each cell.
Co-founders Owen Harris, Greg Hannon and Dario Bressan from the Cancer Grand Challenges team IMAXT received £500k from the Cancer Research Horizons Seed Fund to enable Suil Vision to create a market-ready tool for rollout across institutes and industry. |
| | |
|
|
|
What did you think of this email? |
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
